Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) increases tissue glucose uptake and causes vasodilation independent of insulin. We examined the effect of GLP-1 on muscle microvasculature and glucose uptake. After confirming that GLP-1 potently stimulates nitric oxide (NO) synthase (NOS) phosphorylation in endothelial cells, overnight-fasted adult male rats received continuous GLP-1 infusion (30 pmol/kg/min) for 2 h plus or minus NOS inhibition. Muscle microvascular blood volume (MBV), microvascular blood flow velocity (MFV), and microvascular blood flow (MBF) were determined. Additional rats received GLP-1 or saline for 30 min and muscle insulin clearance/uptake was determined. GLP-1 infusion acutely increased muscle MBV (P < 0.04) within 30 min without altering MFV or femoral blood flow. This effect persisted throughout the 120-min infusion period, leading to a greater than twofold increase in muscle MBF (P < 0.02). These changes were paralleled with increases in plasma NO levels, muscle interstitial oxygen saturation, hind leg glucose extraction, and muscle insulin clearance/uptake. NOS inhibition blocked GLP-1–mediated increases in muscle MBV, glucose disposal, NO production, and muscle insulin clearance/uptake. In conclusion, GLP-1 acutely recruits microvasculature and increases basal glucose uptake in muscle via a NO-dependent mechanism. Thus, GLP-1 may afford potential to improve muscle insulin action by expanding microvascular endothelial surface area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can also enhance the uptake and utilization of glucose in muscle and adipose tissues.207–209”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [207]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 3×
“Incubation of the cells with exendin (9-39) (10 nmol/L), a specific GLP-1 receptor antagonist, completely abolished GLP-1–induced eNOS phosphorylation at Ser(1177), confirming that GLP-1 acted via its receptors (Fig.”
BackgroundRetractedThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 5×
“GLP-1 was given as continuous infusion because of its shorter plasma half-life secondary to rapid degradation by enzyme dipeptidyl peptidase IV (5,31).”
BackgroundMethodInfluentialThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“Activation of the GLP-1 receptors regulates blood glucose concentration by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety (5).”
BackgroundMethodKim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation
Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., Furukawa, S., Tochino, Y., Komuro, R., Matsuda, M., et al. (2007) · Diabetes · doi:10.2337/db06-0911 · Cited by 1,257
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Ye, J., Gao, Z., Yin, J., & He, Q. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2007 · Cited by 840 · cited 2×
“Incubation of the cells with exendin (9-39) (10 nmol/L), a specific GLP-1 receptor antagonist, completely abolished GLP-1–induced eNOS phosphorylation at Ser(1177), confirming that GLP-1 acted via its receptors (Fig.”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 6×
“1): In protocol 1, rats received an intravenous infusion of saline (control) or GLP-1 (7-36) amide (30 pmol/kg/min; Bachem Americas, Inc.”
BackgroundMethodInfluentialEmerging role of adipose tissue hypoxia in obesity and insulin resistance
Ye, J. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.229 · Cited by 543
Cited by
Items 101–200 of 201
Liu, J., Aylor, K. W., & Liu, Z. (2023) · Diabetes · doi:10.2337/db22-0745 · Cited by 30
Self-citationHe, J., Ma, X., Li, W., Liu, Y., & Lin, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107192 · Cited by 30
Short-Chain Fatty Acid Production and Functional Aspects on Host Metabolism
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00002-8 · Cited by 35
Liu, J., Aylor, K. W., Chai, W., Barrett, E. J., & Liu, Z. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00240.2021 · Cited by 30
Self-citationXiong, X., Shao, W., & Jin, T. (2012) · Islets · doi:10.4161/isl.23345 · Cited by 30
Yoshitomi, H., Zhou, J., Nishigaki, T., Li, W., Liu, T., Wu, L., & Gao, M. (2020) · Phytotherapy Research · doi:10.1002/ptr.6685 · Cited by 32
“…© 2020 John Wiley & Sons, Ltd. 2341 activation of GLP-1R in vascular endothelial cells leads to activate the protein kinase A (PKA) and eNOS and release NO to improve blood pressure in experiment models (Chai et al., 2012; Goud, Zhong, Peters, Brook, & Rajagopalan, 2016).”
BackgroundIs vascular insulin resistance an early step in diet-induced whole-body insulin resistance?
Carmichael, L., Keske, M. A., Betik, A. C., Parker, L., Brayner, B., Roberts‐Thomson, K. M., Wadley, G. D., Hamilton, D. L., & Kaur, G. (2022) · Nutrition and Diabetes · doi:10.1038/s41387-022-00209-z · Cited by 26
Sjøberg, K. A., Rattigan, S., Jeppesen, J. F., Lundsgaard, A., Holst, J. J., & Kiens, B. (2015) · The Journal of Physiology · doi:10.1113/jp270129 · Cited by 27
“Recently Chai et al. (2012) showed in the rat that GLP-1 acts via a nitric oxide (NO)-dependent mechanism similar to that utilized by insulin (Vincent et al. 2003) and that the GLP-1-induced changes in MVR could be blunted by a pre-infusion of the NO inhibitor L-NAME (Chai et al. 2012).”
BackgroundMethodResultInfluentialEffect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
Yamada, S., Ogura, Y., Inoue, K., Tanabe, J., Sugaya, T., Ohata, K., Nagai, Y., Natsuki, Y., Hoshino, S., Watanabe, S., et al. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111472 · Cited by 25
Herich, R., Szabóová, R., Karaffová, V., Racines, M. P., Šefcová, M. A., & Larrea-Álvarez, M. (2025) · Microorganisms · doi:10.3390/microorganisms13040784 · Cited by 30
“These metabolites stimulate the secretion of hormones by enteroendocrine cells, which are associated not only with glucose absorption and metabolism but also with enhanced recruitment of skeletal muscle microvasculature [51].”
Clarke, S. J., McCormick, L. M., & Dutka, D. P. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-12 · Cited by 29
“Both GLP-1 (7–36) and (9–36) were vasodilators in mouse coronary arteries, at least in part via a receptor independent mechanism [63] and numerous other groups have identified a potential vasodilatory action of GLP-1 in animals [66-71].”
BackgroundErtuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 26
Owusu, J., & Barrett, E. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147574 · Cited by 27
“It is of interest that GLP-1 and adiponectin each retain microvascular vasodilatory actions in insulin resistant animals, suggesting that these agents may provide avenues for interventions to prevent microvascular insulin resistance.”
BackgroundInfluentialTan, A. W. K., Subaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Patrie, J. T., Aylor, K. W., Basu, A., & Liu, Z. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2017-00446 · Cited by 24
Self-citationAmelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein–Coupled Receptor 5
Cai, Z., Yuan, S., Zhong, Y., Deng, L., Li, J., Tan, X., & Feng, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.637051 · Cited by 23
Manrique, C. M., & Sowers, J. R. (2014) · Cardiorenal Medicine · doi:10.1159/000368423 · Cited by 24
Jia, Z., Zhang, X., Kang, S., & Wu, Y. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0463 · Cited by 23
“Diabetes 49: 500-503. 23. Pulkkinen A, Viitanen L, Kareinen A, Lehto S, Vauhkonen I, et al. (2000) Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease. J Mol Med 78: 372-379. 24. Sandrim VC, de Syllos RW,…”
BackgroundInfluentialMechanistic Causes of Reduced Cardiorespiratory Fitness in Type 2 Diabetes
Abushamat, L. A., McClatchey, P. M., Scalzo, R. L., Schauer, I. E., Huebschmann, A. G., Nadeau, K. J., Liu, Z., Regensteiner, J. G., & Reusch, J. E. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa063 · Cited by 24
Self-citationBerberine improves intralipid-induced insulin resistance in murine
Dong, Z.-H., Lin, H., Chen, F., Che, X.-Q., Bi, W., Shi, S., Wang, J., Gao, L., He, Z., & Zhao, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0493-4 · Cited by 25
Self-citationMuo, I. M., MacDonald, S. D., Madan, R., Park, S.-J., Gharib, A. M., Martinez, P. E., Walter, M. F., Yang, S. B., Rodante, J. A., Courville, A. B., et al. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s182953 · Cited by 21
Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice
Liu, D., Gu, J., Shao, W., Pang, J., Qian, X., & Jin, T. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.08.012 · Cited by 22
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 23
The therapeutic potential of GPR43: a novel role in modulating metabolic health
Cornall, L. M., Mathai, M. L., Hryciw, D. H., & McAinch, A. J. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1419-9 · Cited by 21
Ruze, R., Xu, Q., Liu, G., Li, Y., Chen, W., Cheng, Z., Xiong, Y., Liu, S., Zhang, G., Hu, S., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00126.2021 · Cited by 20
Sato, H., Kubota, N., Kubota, T., Takamoto, I., Iwayama, K., Tokuyama, K., Moroi, M., Sugi, K., Nakaya, K., Goto, M., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4071-8 · Cited by 19
Nathanson, D., Frick, M., Ullman, B., & Nyström, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0116-2 · Cited by 19
The vascular endothelium in diabetes and its potential as a therapeutic target
Liu, Z. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9238-8 · Cited by 19
Self-citationExenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue
Xian, Y., Chen, Z., Deng, H., Cai, M., Liang, H., Xu, W., Weng, J., & Xu, F. L. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0639 · Cited by 18
Hashemi, Z., Yang, K., Yang, H. K., Jin, A., Ozga, J. A., & Chan, C. B. (2014) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2014-0380 · Cited by 20
“…w .n rc re se ar ch pr es s. co m b y SE T O N H A L L U N IV E R SI T Y o n 04 /0 4/ 15 Fo r pe rs on al u se o nl y. glucose in the muscle through a nitric oxide-dependent pathway, although the concentration of the GLP-1 used was higher than the fasting levels seen in our rats (Chai et al. 2012).”
BackgroundYan, F., Yuan, Z., Wang, N., Carey, R. M., Aylor, K. W., Chen, L., Zhou, X., & Liu, Z. (2017) · Endocrinology · doi:10.1210/en.2017-00585 · Cited by 18
Self-citationCardiovascular and hemodynamic effects of glucagon-like peptide-1
Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D. J., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 17
“With regard to microvascular flow and tissue perfusion, GLP-1 has been shown to augment skeletal muscle microvascular blood flow in rats [59, 65] and to augment coronary blood flow in dogs and humans [14, 66], however, it is likely that the vasodilation observed in these experiments was directly related to increases i…”
Roberts‐Thomson, K. M., Betik, A. C., Premilovac, D., Rattigan, S., Richards, S. M., Ross, R. M., Russell, R., Kaur, G., Parker, L., & Keske, M. A. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13237 · Cited by 17
Cardiovascular protective properties of incretin-based therapies in type 2 diabetes
Şimşek, S., & de Galan, B. E. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283590b8f · Cited by 16
Jurowich, C. F., Otto, C., Rikkala, P. R., Wagner, N., Vrhovac, I., Sabolić, I., Germer, C., & Koepsell, H. (2015) · Journal of Diabetes Research · doi:10.1155/2015/490365 · Cited by 15
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“GLP-1 increases microvascular blood volume in rodents (Chai et al. 2012) and recruits microvasculature in human myocardium via a NO-dependent mechanism, in addition to relaxation of the conduit artery (Subaran Sharmila et al. 2014).”
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15
“Additionally, GLP-1RAs promote GLUT4 translocation and improve glucose uptake in skeletal muscle, potentially through this indirect modulation of insulin sensitivity and by reduced glucotoxicity [96,113–115].”
Regulation of Muscle Microcirculation in Health and Diabetes
Liu, Z., Ko, S., Chai, W., & Cao, W. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.2.83 · Cited by 17
“These effects are NO-dependent as inhibition of NO production completely abolishes GLP-1-induced microvascular recruitment and insulin delivery in muscle [33].”
BackgroundSelf-citationTura, A., Bizzotto, R., Yamada, Y., Seino, Y., Pacini, G., & Åhrén, B. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00181.2017 · Cited by 14
Jahn, L. A., Logan, B. R., Love, K. M., Horton, W. B., Eichner, N. Z. M., Hartline, L. M., WELTMAN, A. L., & Barrett, E. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2021 · Cited by 14
Pan, S., Weng, C., Tsai, S.-F., Sheen, Y., Lin, H., Tien, P., Lin, J., Lin, C., Wang, I., & Chou, C. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100734 · Cited by 13
Targeting mitochondria to restore failed adaptation to exercise in diabetes
Geary, K. E., Knaub, L. A., Schauer, I. E., Keller, A. C., Watson, P. A., Miller, M. W., Garat, C., Nadeau, K. J., Cree‐Green, M., Pugazhenthi, S., et al. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130283 · Cited by 14
Nerup, N. A., Ambrus, R., Lindhe, J., Achiam, M. P., Jeppesen, P. B., & Svendsen, L. B. (2017) · Microcirculation · doi:10.1111/micc.12367 · Cited by 13
Li, Q., Chen, J., Li, Y., Chen, T., Zou, J., & Wang, H. (2017) · Medicine · doi:10.1097/md.0000000000007773 · Cited by 13
Reijnders, D., Goossens, G. H., Hermes, G. D. A., Smidt, H., Zoetendal, E. G., & Blaak, E. E. (2018) · Obesity Facts · doi:10.1159/000492114 · Cited by 13
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
“Chai et al (178) demonstrated that GLP‑1 infusion increased PKA activity, promoting the phosphorylation of eNOS, subsequently increasing plasma NO levels, enhancing muscle oxygenation and glucose uptake, and recruiting the microvascular system via NO‑dependent mechanisms, which increased glucose…”
Rajagopal, S., Alruwaili, F., Mavratsas, V., Serna, M. K., Murthy, V. L., & Raji, M. (2023) · Cureus · doi:10.7759/cureus.51352 · Cited by 11
“…of decreased muscle atrophy [20,24,33] and inflammation [21,33] with additional observations of restored myofibrillar architecture [21,29], decreased intramyocellular lipid deposition [32], improvement in muscle vasculature [30,31], and increased preservation of mitochondria in muscle [22].”
Forst, T. M., Michelson, G., Diessel, S., Jahnke, J., & Kapitza, C. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000776 · Cited by 11
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 11
Stabilizing Cellular Barriers: Raising the Shields Against COVID-19
Hanchard, J., Capó-Vélez, C. M., Deusch, K., Lidington, D., & Bolz, S.-S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.583006 · Cited by 10
Yates, T., Henson, J., Sargeant, J., King, J. A., Ahmad, E., Zaccardi, F., & Davies, M. J. (2021) · Translational Medicine and Exercise Prescription · doi:10.53941/tmep.v1i1.33 · Cited by 10
CrossTalk proposal: De novo capillary recruitment in healthy muscle is necessary
Barrett, E. J., Keske, M. A., Rattigan, S., & Eringa, E. C. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.282137 · Cited by 9
“Adiponectin (Zhao et al. 2013), Glucagon-like peptide-1 (Chai et al. 2012) and angiotensin II (via its type 2 receptor; Chai et al. 2010) each increase microvascular perfused volume and enhance skeletal muscle nutrient and oxygen delivery.”
BackgroundDeciphering ventricular GLP-1 action: time for a change of heart
Ussher, J. R. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00680.2014 · Cited by 9
“delivery (5, 16, 19), though that would not explain findings in”
BackgroundBernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
“Muscle perfusion is also favored via PKA-mediated endothelial nitric oxide synthase (eNOS) activation, which induces vasodilation and consequently increases insulin delivery [31].”
BackgroundFeline Diabetes Is Associated with Deficits in Markers of Insulin Signaling in Peripheral Tissues
Patra, S., McMillan, C. J., Snead, E. R., Warren, A. L., Cosford, K., & Chelikani, P. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313195 · Cited by 9
Cornall, L. M., Hryciw, D. H., Mathai, M. L., & McAinch, A. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.006 · Cited by 8
“Given that GLP-1 promotes glucose stimulated insulin secretion, cardiac muscle glucose uptake and has been shown to be cardioprotective (Chai et al., 2012; Liu et al., 2010; Zhao et al., 2006), the indirect effects of GPR119 agonism secondary to increased plasma GLP-1 may improve cardiac muscle…”
Bank, N. C., Whittingslow, D. C., Duggan, S., Morningstar, J. L., & Weinberg, D. S. (2025) · World Neurosurgery · doi:10.1016/j.wneu.2025.124751 · Cited by 9
Katsanos, C. S., Liu, Z., & Atherton, P. J. (2026) · Comprehensive physiology · doi:10.1002/cph4.70126 · Cited by 8
“…(Subaran et al. 2014; Chai et al. 2012; Abdulla et al. 2020) by increasing nitric oxide (NO) bioavailability via endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1177 (Chai et al. 2012), and where NO signaling leads to vasodilation and recruitment of nutritive microvasculature.”
InfluentialSelf-citationThe role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
“Incubation of bovine aortic endothelial cells with GLP-1 increases Akt phosphorylation and subsequently stimulates eNOS phosphorylation [82].”
Kim, J. H. (2020) · Physiological Research · doi:10.33549/physiolres.934480 · Cited by 7
Ide, S., Yamamoto, M., Takemoto, M., Fujimoto, M., Ide, K., Kobayashi, K., & Yokote, K. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13970 · Cited by 7
Clarke, S. J., Pettit, S., Giblett, J. P., Zhao, T. X., Kydd, A. C., Albrechtsen, N. J. W., Deacon, C. F., Parameshwar, J. K., & Hoole, S. P. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.013 · Cited by 7
Dimeric styrylpyrones with stimulating GLP-1 secretion activities from Alpinia kwangsiensis
Wu, M.-Z., Gongpan, P., Dai, M.-Y., Sun, P., Huang, T.-P., Xu, Y., Xiao, C., Li, J. X., Sun, Y., & Ji, K. (2022) · Tetrahedron · doi:10.1016/j.tet.2022.132901 · Cited by 6
Complex vasoactivity of liraglutide. Contribution of three gasotransmitters
Sélley, E., Molnár, G. A., Kun, S., Szijártó, I. A., Laczy, B., Kovács, T., Fülöp, F., & Wittmann, I. (2015) · Artery Research · doi:10.1016/j.artres.2015.04.001 · Cited by 7
Diabetes Pharmacotherapy and its effects on the Skeletal Muscle Energy Metabolism
Yu, B., Wang, D., Zhou, J., Huang, R., Cai, T., Hu, Y., Zhou, Y., & Ma, J. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575299439240216081711 · Cited by 5
Koshinaka, K., Ando, R., & Satô, A. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-98 · Cited by 5
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
Ölmestig, J. N. E., Marlet, I. R., Vilsbøll, T., Rungby, J., Rostrup, E., Lambertsen, K. L., & Kruuse, C. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899389 · Cited by 4
“, 2014), apparently nitric oxide-dependent (Chai et al., 2012).”
BackgroundPotential Role of GLP-1 Based Therapeutics in Coronary Artery Disease
Xiong, Q., Wang, J., Huang, K., Li, W., & Zhang, L. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811315 · Cited by 4
“This effect is believed to be facilitated by a process that relies on nitric oxide, as evidenced by the utilization of contrast-enhanced ultrasound imaging [29].”
BackgroundAmasa, S., Agrawal, V., Karabacak, M., Bhimani, A. D., Le, C., Margetis, K. D., & Houten, J. K. (2026) · Journal of Spine Surgery · doi:10.21037/jss-25-142 · Cited by 5
“Studies in both animal models and human subjects have shown that GLP-1 agonists improve microvascular recruitment and blood flow through endothelial nitric oxide synthase (eNOS) activation, mediated by protein kinase A signaling pathways (45-47).”
GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Ramadurgum, P., Sharma, K. M., Pinon, A., Kattamuri, L. P. V., & Botros, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02356-6 · Cited by 3
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
“186 187-189 Therefore, rather than direct genomic reprogramming of myosin heavy chain (MHC) isoforms as observed in animals, 190 the human “fiber-type transition” likely represents a functional oxidative remodeling mediated through the vascular system.”
Self-citationNiazi, S., Gnesin, F., Jawad, B. N., Niazi, Z., Yazdanfard, P. D. W., Toft‐Petersen, A. P., Sørensen, K. K., Meaidi, A., Subhi, Y., & Torp-Pedersen, C. T. (2026) · Acta Ophthalmologica · doi:10.1111/aos.70168 · Cited by 3
GLP‐1 and GIP Beyond Glycaemia: Evolutionary Roles in Energy Optimisation and Organ Protection
Tuccinardi, D., Watanabe, M., Masi, D., Gianfrilli, D., Manfrini, S., & le Roux, C. W. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70108 · Cited by 3
Incretin-mediated control of cardiac energy metabolism
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0011 · Cited by 2
Pleiotropic effects of incretins and antidiabetics with incretine mechanism
Winkler, G. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29553 · Cited by 2
The Skeletal Muscle Microvasculature and Its Effects on Metabolism
Kolka, C. M. (2016) · InTech eBooks · doi:10.5772/63535 · Cited by 3
“GLP‐1 receptor agonists have beneficial effects on the vasculature [74–78] and metabolism of glucose [70, 71, 79–81]; though whether this reflects a direct effect on glucose metabolism, an indirect effect through blood flow changes, or a combination of these is not clear.”
BackgroundKhroud, M., Song, Z., Shao, W., & Jin, T. (2019) · Obesity Medicine · doi:10.1016/j.obmed.2019.100153 · Cited by 2
Cellular Basis of Insulin Resistance: A Tale of the Microvasculature
Liu, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819801-8.00015-6 · Cited by 2
Self-citationAvogaro, A. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70184 · Cited by 2
“30 For GIP, evidence is limited.”
Incretin-based therapies for the failing heart
Ussher, J. R., & Campbell, J. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000086 · Cited by 1
The Role of Transcription Factor 7-Like 2 in Hepatic Glucose Metabolism
Ip, W. (2014) · TSpace (University of Toronto)
Changes in Postprandial Blood Pressure in the Elderly
Filho, S. R. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418680-4.00030-0
Effects of Exercise on Incretin Hormones
Toghi-Eshghi, S. R. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r30g3hd88
GLP-1R Agonists & Cardiac Energy Metabolism in Type 2 Diabetes
Almutairi, M. G. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-fhr3-cr50
Functional Study on the GLP-1 Based Drug Liraglutide in High Fat Diet Fed Mice
Khroud, M. (2020) · TSpace (University of Toronto)
Nutritional Approaches and Gastrointestinal Health and Physiology
Saqui–Salces, M. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Therapeutic potential of zein-based nanoparticles
Reboredo, C. (2022) · doi:10.15581/10171/62894
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Lagutina, D. D., Stepanova, T. V., Савкина, А. А., & Иванов, А. Н. (2021) · Saratov Medical Journal · doi:10.15275/sarmj.2021.0304
“…the positive effects of liraglutide on microcirculation, revealed in the course of our study, may be associated with the normalization of carbohydrate metabolism, which prevents further alteration of endothelial cells [17], or else – with direct endothelium-protective effect of liraglutide [18].”
BackgroundMethodTherapeutic Management of Type 2 Diabetes: The Nitric Oxide Axis
Ranjbar, T., O’Connor, J. L., & Kashfi, K. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815079814122010013
Il ruolo dei progenitori delle cellule endoteliali nel diabete mellito
Longo, M., Maio, A., Botta, G., Caruso, P., & Esposito, K. (2023) · il Diabete · doi:10.30682/ildia2303f
Tan, A. W. K., Jahn, L. A., Hartline, L. M., Aylor, K. W., & Liu, Z. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2025
Self-citationGrau Bové, M. C. (2021) · Rovira & Virgili repository · Cited by 2
Cohen, J. (2021) · The Atrium (University of Guelph)
Mohamed, A. B. (2018) · theses.fr (ABES) · doi:10.70675/8206031dz8e5dz47a9z965az67fe5f7e19b6 · Cited by 2
Rôle des anses intestinales dans les effets métaboliques du gastric bypass : apport du modèle porcin
Marciniak, C. (2021) · theses.fr (ABES) · doi:10.70675/20ef750cz9657z4a87z8af5zc19b622f8793
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
GIP Acutely Blunts Insulin- and GLP-1–Induced Muscle Microvascular Perfusion
Liu, J., Chun, C., Sin, T. K., Zhao, F., Aylor, K. W., Tushi, N. J., Sun, S., & Liu, Z. (2026) · Diabetes · doi:10.2337/db25-1009
Self-citationLiu, P.-Y., Shih, C.-K., Hsieh, M. H., Lin, C., Liu, C. L., Lai, E. C., Li, C., Yu, C.-H., & Sung, J. (2026) · Nature Communications · doi:10.1038/s41467-026-76083-5
“…actions of GLP-1RAs include attenuation of systemic in fl ammatory mediators and improvements in endothelial or microvascular function 40 – 42 , with additional signals suggesting modulation of platelet activation and reduced ischemic injury in proof-of-concept myocardial infarction…”
Metadata
- Authors
- Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z.
- Affiliations
- University of Virginia Health System (US)
- Shandong University (CN)
- Central South University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Liu, Zhenqi
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-03-14
- Volume
- 61
- Issue
- 4
- Pages
- 888-896
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3314347
- OpenAlex
- W2130375560
- Cited by
- 194
- References
- 47
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 9 · 2023: 9 · 2022: 11 · 2021: 17 · 2020: 13 · 2019: 9 · 2018: 17 · 2017: 8 · 2016: 13 · 2015: 15 · 2014: 24 · 2013: 23 · 2012: 6
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (1-11-CR-30, 9-09-NOVO-11)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL094722)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- glucagon-like peptide-1, nitric oxide, nitric oxide synthase, muscle microvasculature, muscle glucose uptake, microvascular blood flow, endothelial cells, insulin clearance, insulin resistance, vasodilation, glucose extraction
- MeSH terms
- Animals, Aorta, Cattle, Cells, Cultured, Drug Administration Schedule, Gene Expression Regulation, Glucose, Hormones, Insulin, Male, Nitric Oxide, Somatostatin, Rats, Sprague-Dawley, Cyclic AMP-Dependent Protein Kinases, Muscle, Skeletal, NG-Nitroarginine Methyl Ester, Endothelial Cells, Proto-Oncogene Proteins c-akt, Rats, Glucagon-Like Peptide 1, Nitric Oxide Synthase Type III, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.